Skip to main content

Advertisement

Table 3 Ongoing phase III trials for durvalumab in non-small cell lung cancer

From: Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer

Identifier Title Interventions Study design Population Primary endpoint Secondary endpoint Status Primary Completion
NCT03800134 A study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small cell lung cancer (AEGEAN) Durvalumab + platinum-based chemotherapy
Placebo + platinum-based chemotherapy
Randomized parallel trial Resectable stage IIA–IIIB NSCLC MPR pCR, OS, DFS Recruiting 27-Jul -20
NCT03519971 Study of durvalumab given with chemoradiation therapy in patients with unresectable non-small cell lung cancer (PACIFIC2) Durvalumab + platinum-based chemotherapy and radiation
Placebo + platinum-based chemotherapy and radiation
Randomized parallel trial Unresectable locally advanced stage III NSCLC PFS, ORR OS, DOR, PFS2 Recruiting 30-Sep-20
NCT02273375 Double blind placebo controlled study of adjuvant MEDI4736 in completely resected NSCLC Durvalumab
Placebo
Randomized parallel trial Stage IB (> 4 cm) to IIIA NSCLC after complete surgical resection DFS OS, LCSS Recruiting Jan-23
NCT03706690 A study of durvalumab as consolidation therapy in non-small cell lung cancer patients (PACIFIC5) Durvalumab
Placebo
Randomized parallel trial Unresectable locally advanced stage III NSCLC PFS OS, ORR, DOR Recruiting 25-Mar-21
NCT03164616 Study of durvalumab + tremelimumab with chemotherapy or durvalumab with chemotherapy or chemotherapy alone for patients with lung cancer (POSEIDON) Durvalumab + tremelimumab
Durvalumab monotherapy + SoC
SoC chemotherapy alone
Randomized parallel trial Untreated advanced NSCLC without activating EGFR mutation or ALK fusions PFS, OS ORR, DOR, Recruiting 30-Sep-19
NCT03003962 Study of durvalumab alone or chemotherapy for patients with advanced non small-cell lung cancer Durvalumab
SoC chemotherapy
Randomized parallel trial Untreated advanced PD-L1 positive NSCLC without EGFR mutation and ALK rearrangement OS ORR, DOR, PFS Active, not recruiting 30-Sep-19
NCT02453282 Phase III open label first line therapy study of MEDI 4736 (durvalumab) with or without tremelimumab versus soc in non-small-cell lung cancer (MYSTIC) Durvalumab
Durvalumab + tremelimumab
SoC chemotherapy
Randomized parallel trial Untreated advanced NSCLC without activating EGFR mutation or ALK fusions OS, PFS ORR Active, not recruiting 4-Oct-18
NCT02542293 Study of 1st Line Therapy Study of Durvalumab With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) Durvalumab + tremelimumab
SoC chemotherapy
Randomized parallel trial Untreated advanced NSCLC without activating EGFR mutation or ALK fusions OS PFS, ORR, DOR Active, not recruiting 22-Aug-19
  1. Durvalumab is currently being investigated in combination with different immunotherapies
  2. DCR disease control rate, LCSS lung cancer-specific survival, PFS2 time from randomization to second progression, TTD/TTM time to death/time to distant metastasis, MPR major pathological response, pCR pathological, complete response, DFS disease-free survival